AAAAAA

   
Results: 1-25 | 26-40 |
Results: 26-40/40
RANDOMIZED PHASE-III TRIAL OF EDATREXATE VERSUS METHOTREXATE IN PATIENTS WITH METASTATIC AND OR RECURRENT SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK - A EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER HEAD AND NECK-CANCER COOPERATIVE GROUP-STUDY/
Authors: SCHORNAGEL JH VERWEIJ J DEMULDER PHM COGNETTI F VERMORKEN JB CAPPELAERE P ARMAND JP WILDIERS J DEGRAEFF A CLAVEL M SAHMOUD T KIRKPATRICK A LEFEBVRE JL
Citation: Jh. Schornagel et al., RANDOMIZED PHASE-III TRIAL OF EDATREXATE VERSUS METHOTREXATE IN PATIENTS WITH METASTATIC AND OR RECURRENT SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK - A EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER HEAD AND NECK-CANCER COOPERATIVE GROUP-STUDY/, Journal of clinical oncology, 13(7), 1995, pp. 1649-1655
CARRIER-MEDIATED AND RECEPTOR-MEDIATED TRANSPORT OF FOLATE ANTAGONISTS TARGETING FOLATE-DEPENDENT ENZYMES - CORRELATES OF MOLECULAR-STRUCTURE AND BIOLOGICAL-ACTIVITY
Authors: WESTERHOF GR SCHORNAGEL JH KATHMANN I JACKMAN AL ROSOWSKY A FORSCH RA HYNES JB BOYLE FT PETERS GJ PINEDO HM JANSEN G
Citation: Gr. Westerhof et al., CARRIER-MEDIATED AND RECEPTOR-MEDIATED TRANSPORT OF FOLATE ANTAGONISTS TARGETING FOLATE-DEPENDENT ENZYMES - CORRELATES OF MOLECULAR-STRUCTURE AND BIOLOGICAL-ACTIVITY, Molecular pharmacology, 48(3), 1995, pp. 459-471
TOMUDEX (ZD1694), A NOVEL AND SPECIFIC THYMIDYLATE SYNTHASE INHIBITORHAS PROMISING ACTIVITY IN ADVANCED COLORECTAL-CANCER
Authors: VANCUTSEM E CUNNINGHAM D ZALCBERG J FRANCOIS E SCHORNAGEL JH ADENIS A GREEN M STARKHAMMER H AZAB M
Citation: E. Vancutsem et al., TOMUDEX (ZD1694), A NOVEL AND SPECIFIC THYMIDYLATE SYNTHASE INHIBITORHAS PROMISING ACTIVITY IN ADVANCED COLORECTAL-CANCER, Gastroenterology, 108(4), 1995, pp. 548-548
FUNCTIONAL-ACTIVITY OF THE REDUCED FOLATE CARRIER IN KB, MA104, AND IGROV-I CELLS EXPRESSING FOLATE-BINDING PROTEIN
Authors: WESTERHOF GR RIJNBOUTT S SCHORNAGEL JH PINEDO HM PETERS GJ JANSEN G
Citation: Gr. Westerhof et al., FUNCTIONAL-ACTIVITY OF THE REDUCED FOLATE CARRIER IN KB, MA104, AND IGROV-I CELLS EXPRESSING FOLATE-BINDING PROTEIN, Cancer research, 55(17), 1995, pp. 3795-3802
HIGH-DOSE CARBOPLATIN, THIOTEPA AND CYCLOPHOSPHAMIDE (CTC) WITH PERIPHERAL-BLOOD STEM-CELL SUPPORT IN THE ADJUVANT THERAPY OF HIGH-RISK BREAST-CANCER - A PRACTICAL APPROACH
Authors: VANDERWALL E NOOIJEN WJ BAARS JW HOLTKAMP MJ SCHORNAGEL JH RICHEL DJ RUTGERS EJT SLAPERCORTENBACH ICM VANDERSCHOOT CE RODENHUIS S
Citation: E. Vanderwall et al., HIGH-DOSE CARBOPLATIN, THIOTEPA AND CYCLOPHOSPHAMIDE (CTC) WITH PERIPHERAL-BLOOD STEM-CELL SUPPORT IN THE ADJUVANT THERAPY OF HIGH-RISK BREAST-CANCER - A PRACTICAL APPROACH, British Journal of Cancer, 71(4), 1995, pp. 857-862
THE ROLE OF HEALTH-CARE PROVIDERS AND SIGNIFICANT OTHERS IN EVALUATING THE QUALITY-OF-LIFE OF PATIENTS WITH CANCER
Authors: SNEEUW KCA DETMAR SB SPRANGERS MAG SCHORNAGEL JH AARONSON NK
Citation: Kca. Sneeuw et al., THE ROLE OF HEALTH-CARE PROVIDERS AND SIGNIFICANT OTHERS IN EVALUATING THE QUALITY-OF-LIFE OF PATIENTS WITH CANCER, Quality of life research, 3(1), 1994, pp. 93-93
BONE-MARROW RECONSTITUTION AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS PERIPHERAL-BLOOD PROGENITOR-CELL TRANSPLANTATION - EFFECT OF GRAFT SIZE
Authors: VANDERWALL E RICHEL DJ HOLTKAMP MJ SLAPERCORTENBACH ICM VANDERSCHOOT CE DALESIO O NOOIJEN WJ SCHORNAGEL JH RODENHUIS S
Citation: E. Vanderwall et al., BONE-MARROW RECONSTITUTION AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS PERIPHERAL-BLOOD PROGENITOR-CELL TRANSPLANTATION - EFFECT OF GRAFT SIZE, Annals of oncology, 5(9), 1994, pp. 795-802
RANDOMIZED COMPARISON OF CISPLATIN, METHOTREXATE, BLEOMYCIN AND VINCRISTINE (CABO) VERSUS CISPLATIN AND 5-FLUOROURACIL (CF) VERSUS CISPLATIN (C) IN RECURRENT OR METASTATIC SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK - A PHASE-III STUDY OF THE EORTC HEAD AND NECK-CANCER COOPERATIVE GROUP
Authors: CLAVEL M VERMORKEN JB COGNETTI F CAPPELAERE P DEMULDER PHM SCHORNAGEL JH TUENI EA VERWEIJ J WILDIERS J CLERICO M DALESIO O KIRKPATRICK A SNOW GB
Citation: M. Clavel et al., RANDOMIZED COMPARISON OF CISPLATIN, METHOTREXATE, BLEOMYCIN AND VINCRISTINE (CABO) VERSUS CISPLATIN AND 5-FLUOROURACIL (CF) VERSUS CISPLATIN (C) IN RECURRENT OR METASTATIC SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK - A PHASE-III STUDY OF THE EORTC HEAD AND NECK-CANCER COOPERATIVE GROUP, Annals of oncology, 5(6), 1994, pp. 521-526
A PHASE-II STUDY OF PIRARUBICIN IN PATIENTS WITH ADVANCED RECURRENT HEAD AND NECK SQUAMOUS-CELL CARCINOMA
Authors: DEMULDER PHM CAPPELAERE P COGNETTI F VERWEIJ J SCHORNAGEL JH VERMORKEN JB KIRKPATRICK A LEFEBVRE JL
Citation: Phm. Demulder et al., A PHASE-II STUDY OF PIRARUBICIN IN PATIENTS WITH ADVANCED RECURRENT HEAD AND NECK SQUAMOUS-CELL CARCINOMA, Cancer chemotherapy and pharmacology, 33(5), 1994, pp. 438-440
CHARACTERIZATION OF RESISTANCE MECHANISMS TO CIS-DIAMINEDICHLOROPLATINUM(II) IN 3 SUBLINES OF THE CC531 COLON ADENOCARCINOMA CELL-LINE IN-VITRO
Authors: OLDENBURG J BEGG AC VANVUGT MJH RUEVEKAMP M SCHORNAGEL JH PINEDO HM LOS G
Citation: J. Oldenburg et al., CHARACTERIZATION OF RESISTANCE MECHANISMS TO CIS-DIAMINEDICHLOROPLATINUM(II) IN 3 SUBLINES OF THE CC531 COLON ADENOCARCINOMA CELL-LINE IN-VITRO, Cancer research, 54(2), 1994, pp. 487-493
LEUCOVORIN RESCUE OF HUMAN CANCER AND BONE-MARROW CELLS FOLLOWING EDATREXATE OR METHOTREXATE
Authors: JOLIVET J JANSEN G PETERS GJ PINARD MF SCHORNAGEL JH
Citation: J. Jolivet et al., LEUCOVORIN RESCUE OF HUMAN CANCER AND BONE-MARROW CELLS FOLLOWING EDATREXATE OR METHOTREXATE, Biochemical pharmacology, 47(4), 1994, pp. 659-665
FEASIBILITY STUDY OF FEC-CHEMOTHERAPY WITH DOSE-INTENSIVE EPIRUBICIN AS INITIAL TREATMENT IN HIGH-RISK BREAST-CANCER
Authors: VANDERWALL E RICHEL DJ KUSUMANTO YH RUTGERS EJT SCHORNAGEL JH SCHAAKEKONING CCE PETERSE JL RODENHUIS S
Citation: E. Vanderwall et al., FEASIBILITY STUDY OF FEC-CHEMOTHERAPY WITH DOSE-INTENSIVE EPIRUBICIN AS INITIAL TREATMENT IN HIGH-RISK BREAST-CANCER, Annals of oncology, 4(9), 1993, pp. 791-792
CLINICAL PHARMACOKINETICS OF ANTI-METABOLITES
Authors: PETERS GJ SCHORNAGEL JH MILANO GA
Citation: Gj. Peters et al., CLINICAL PHARMACOKINETICS OF ANTI-METABOLITES, Cancer surveys, 17, 1993, pp. 123-156
DRUG-INDUCED DNA MODIFICATION IN BUCCAL CELLS OF CANCER-PATIENTS RECEIVING CARBOPLATIN AND CISPLATIN COMBINATION CHEMOTHERAPY, AS DETERMINED BY AN IMMUNOCYTOCHEMICAL METHOD - INTERINDIVIDUAL VARIATION AND CORRELATION WITH DISEASE RESPONSE
Authors: BLOMMAERT FA MICHAEL C TERHEGGEN PMAB MUGGIA FM KORTES V SCHORNAGEL JH HART AAM DENENGELSE L
Citation: Fa. Blommaert et al., DRUG-INDUCED DNA MODIFICATION IN BUCCAL CELLS OF CANCER-PATIENTS RECEIVING CARBOPLATIN AND CISPLATIN COMBINATION CHEMOTHERAPY, AS DETERMINED BY AN IMMUNOCYTOCHEMICAL METHOD - INTERINDIVIDUAL VARIATION AND CORRELATION WITH DISEASE RESPONSE, Cancer research, 53(23), 1993, pp. 5669-5675
A PHASE-II TRIAL OF 10-ETHYL-10-DEAZA-AMINOPTERIN, A NOVEL ANTIFOLATE, IN PATIENTS WITH ADVANCED AND OR RECURRENT SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK
Authors: SCHORNAGEL JH VERWEIJ J DEMULDER PHM COGNETTI F VERMORKEN JB CAPPELAERE P ARMAND JP WILDIERS J CLAVEL M KIRKPATRICK A LEFEBVRE JL
Citation: Jh. Schornagel et al., A PHASE-II TRIAL OF 10-ETHYL-10-DEAZA-AMINOPTERIN, A NOVEL ANTIFOLATE, IN PATIENTS WITH ADVANCED AND OR RECURRENT SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK, Annals of oncology, 3(3), 1992, pp. 223-226
Risultati: 1-25 | 26-40 |